WARNINGS AND PRECAUTIONS

• Use atazanavir 300 mg with more caution in patients with preexisting conduction system disease or when administered with other drugs that may prolong the PR interval.
• Patients who are carrying hepatitis B or hepatitis C infection are more likely at risk of increased transaminases or hepatic decompensation.
• Prior to therapy and during treatment, patients should be monitored for hepatic laboratory tests.
• Atavir should be used with caution in patients with mild to moderate hepatic impairment. Do not use ATAZANAVIR 300mg in patients with severe hepatic impairment.
• No dose adjustment is required for postpartum patients. Also, patients must be closely and watchfully monitored for adverse events because atazanavir exposures could be higher during the first couple of months after delivery.
• Atavir should be discontinued if severe rash develops. Cases of Stevens-Johnson syndrome, erythema multiforme, and toxic skin eruptions have been reported in patients receiving Atavir.
• This antiretroviral is distinguished from other Protease Inhibitors in that it has very less effects on lipid profile and also appears to be less responsible for lipodystrophy.
• When Atazanavir is boosted with ritonavir, it also reduces the metabolic advantages of atazanavir.
• Atazanavir is contraindicated in patients with previous hypersensitivity (e.g., erythema multiforme, toxic skin eruptions and Stevens-Johnson syndrome). Also, atazanavir should not be given with rifampin, alfuzosin, lurasidone, irinotecan, pimozide, triazolam, orally administered midazolam, cisapride, St. John’s wort, ergot derivatives, lovastatin, simvastatin, sildenafil, nevirapine or indinavir.
• The data is not sufficient in order to determine whether there are any effects of race on the pharmacokinetics of atazanavir.